Opinion

Video

Optimizing Overall Health During CLL Management

Author(s):

Yuliya P.L Linhares, MD,Josie Montegaard, MSN, AGPCNP-BC

Yuliya Linhares, MD, discusses how healthy lifestyle choices, such as diet and exercise, can play a valuable role in optimizing CLL treatment outcomes.

Video content above is prompted by the following question(s):

  • What questions or concerns do patients have when starting treatment for chronic lymphocytic leukemia (CLL)? How might treatment affect their daily activities?
  • When and how are patients with CLL monitored?
  • How do you counsel patients about living with a chronic cancer like CLL and the potential need to remain on treatment?
Related Videos
A panel of 3 experts on CML
Related Content
Illustration of red blood cells.
October 10th 2024

Jaypirca Plus Venclexta With or Without Rituxan May Be Beneficial in r/r CLL

Alex Biese
A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Illustration of a man with round glasses and a goatee.
October 7th 2024

My Bitter Chemotherapy Pills for Chronic Lymphocytic Leukemia

Chester Freeman
I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Illustration of CLL cells.
September 17th 2024

Treatment Switching May Be Less Likely With Brukinsa vs Other BTK Inhibitors in CLL/SLL

Jax DiEugenio
Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.
Illustration of chronic lymphocytic leukemia cells.
August 26th 2024

FDA Fast Tracks BGB-16673 for CLL, SLL

Brielle Benyon
The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.